A look at Cytokinetics Inc’s (CYTK) recent performance gives investors their first glimpse of hope.

On Monday, Cytokinetics Inc (NASDAQ: CYTK) opened lower -3.75% from the last session, before settling in for the closing price of $34.66. Price fluctuations for CYTK have ranged from $29.31 to $61.38 over the past 52 weeks.

Healthcare Sector giant saw their annual sales slid by -20.02% over the last five years. Company’s average yearly earnings per share was noted -8.95% at the time writing. With a float of $116.79 million, this company’s outstanding shares have now reached $119.22 million.

The firm has a total of 498 workers. Let’s measure their productivity. In terms of profitability, gross margin is -1359.51%, operating margin of -2943.3%, and the pretax margin is -3201.47%.

Cytokinetics Inc (CYTK) Insider Activity

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cytokinetics Inc is 2.21%, while institutional ownership is 116.07%. The most recent insider transaction that took place on Jul 01 ’25, was worth 167,750. In this transaction President & CEO of this company sold 5,000 shares at a rate of $33.55, taking the stock ownership to the 398,108 shares. Before that another transaction happened on Jun 17 ’25, when Company’s EVP Research & Development sold 2,000 for $32.91, making the entire transaction worth $65,820. This insider now owns 140,610 shares in total.

Cytokinetics Inc (CYTK) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.39 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -8.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.60% during the next five years compared to -20.02% drop over the previous five years of trading.

Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators

Check out the current performance indicators for Cytokinetics Inc (CYTK). In the past quarter, the stock posted a quick ratio of 5.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 207.29.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.31, a number that is poised to hit -1.42 in the next quarter and is forecasted to reach -5.06 in one year’s time.

Technical Analysis of Cytokinetics Inc (CYTK)

Analysing the last 5-days average volume posted by the [Cytokinetics Inc, CYTK], we can find that recorded value of 1.34 million was lower than the volume posted last year of 1.82 million. As of the previous 9 days, the stock’s Stochastic %D was 70.65%.

During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 18.06%, which indicates a significant decrease from 44.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.29% in the past 14 days, which was lower than the 57.39% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $33.64, while its 200-day Moving Average is $44.55. Now, the first resistance to watch is $34.26. This is followed by the second major resistance level at $35.17. The third major resistance level sits at $35.76. If the price goes on to break the first support level at $32.76, it is likely to go to the next support level at $32.17. Should the price break the second support level, the third support level stands at $31.26.

Cytokinetics Inc (NASDAQ: CYTK) Key Stats

There are currently 119,427K shares outstanding in the company with a market cap of 3.98 billion. Presently, the company’s annual sales total 18,470 K according to its annual income of -589,530 K. Last quarter, the company’s sales amounted to 1,580 K and its income totaled -161,380 K.